BLTE

Belite Bio Inc

Add to Watchlist

Advanced Chart

105.905

+7.805(7.956%)1D

Line

Candle

YTD

High

107.000

Open

98.850

VWAP

101.57

Vol

135.99K

Mkt Cap

3.68B

Low

97.985

Amount

13.81M

EV/EBITDA(TTM)

Total Shares

29.79M

3.54B

EV/OCF(TTM)

P/S(TTM)

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-0.490

+75%

-0.487

+52.08%

-0.470

+4.44%

Estimates Revision

The market is revising No Change the revenue expectations for Belite Bio, Inc (BLTE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 51.75%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-6.18%

In Past 3 Month

Stock Price

Go Up

+51.75%

In Past 3 Month

4 Analyst Rating

-11.95% Downside

Wall Street analysts forecast BLTE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLTE is 93.25 USD with a low forecast of 80.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

-11.95% Downside

Current: 105.905

Low

80.00

Averages

93.25

High

110.00

-11.95% Downside

Current: 105.905

Low

80.00

Averages

93.25

High

110.00

Bruce Jackson

Buy

maintain

$80 -> $132

2025-10-31

New

Reason

Bruce Jackson

Price Target

$80 -> $132

2025-10-31

New

maintain

Buy

Reason

Benchmark analyst Bruce Jackson raised the firm's price target on Belite Bio to $132 from $80 and keeps a Buy rating on the shares. Belite is "approaching a series of major catalysts," beginning with the release of topline results during Q4 from the Phase 3 DRAGON study of Tinlarebant in Stargardts Disease, the analyst tells investors. The results, which are likely to be positive in the firm's view, combined with orphan drug designation, could result in attractive pricing, leading the firm to increase its pricing assumptions for the drug.

H.C. Wainwright

Buy

downgrade

$100 -> $98

2025-09-15

Reason

H.C. Wainwright

Price Target

$100 -> $98

2025-09-15

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Belite Bio to $98 from $100 and keeps a Buy rating on the shares. The firm cites higher shares outstanding post the equity financing for the target cut.

Benchmark

Bruce Jackson

Strong Buy

Reiterates

$80

2025-03-26

Reason

Benchmark

Bruce Jackson

Price Target

$80

2025-03-26

Reiterates

Strong Buy

Reason

Benchmark raised the firm's price target on Belite Bio to $80 from $79 and keeps a Buy rating on the shares. In February, Belite received a positive report from an interim data analysis of the Phase 3 DRAGON trial and a DSMB recommendation to seek accelerated regulatory approval, notes the analyst, who calls out completion of the DRAGON II study around mid-year and completion of the DRAGON study by year-end 2025 as the next major catalysts for the shares.

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$100

2025-03-18

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$100

2025-03-18

Reiterates

Strong Buy

Reason

Cantor Fitzgerald

Jennifer Kim

Buy

Reiterates

n/a

2025-03-18

Reason

Cantor Fitzgerald

Jennifer Kim

Price Target

n/a

2025-03-18

Reiterates

Buy

Reason

Benchmark

Bruce Jackson

Strong Buy

Maintains

$57 → $79

2025-01-21

Reason

Benchmark

Bruce Jackson

Price Target

$57 → $79

2025-01-21

Maintains

Strong Buy

Reason

Benchmark raised the firm's price target on Belite Bio to $79 from $57 and keeps a Buy rating on the shares. After speaking to management at a conference last week, the firm revisited its pricing assumptions for Tinlarebant in the treatment of Stargardt disease type 1 and now assumes an average price of $50,000, the analyst tells investors.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Belite Bio Inc (BLTE.O) is -55.25, compared to its 5-year average forward P/E of -34.62. For a more detailed relative valuation and DCF analysis to assess Belite Bio Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-34.62

Current PE

-55.25

Overvalued PE

-24.53

Undervalued PE

-44.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

11.70

Current PS

105.91

Overvalued PS

57.77

Undervalued PS

-34.36

Financials

Annual

Quarterly

FY2025Q2

YoY :

+68.05%

-17.60M

Operating Profit

FY2025Q2

YoY :

+71.90%

-16.32M

Net Income after Tax

FY2025Q2

YoY :

+61.29%

-0.50

EPS - Diluted

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

BLTE News & Events

Events Timeline

2025-11-02 (ET)

2025-11-02

10:32:46

Belite Bio reveals that the U.K. MHRA has accepted the CMA application for Tinlarebant.

2025-10-15 (ET)

2025-10-15

14:52:43

Leerink Optimistic About Belite Bio, Calls Tinlarebant News a Positive Development

2025-10-15

08:02:00

Belite Bio reveals that China's NMPA has approved the NDA submission for Tinlarebant.

News

9.0

11-02Newsfilter

PinnedBelite Bio Secures Conditional Marketing Authorization Application Approval from UK Medicines and Healthcare Products Regulatory Agency for Tinlarebant in Stargardt Disease Treatment Based on Interim Analysis Results